Chondroitin sulphate;Condroitín sulfato

DOLOR

Volumn 19, Issue 3, 2004, Pages 141-150

  Möller, Ingrid ^a   Martinez G ^b   Verges, J ^b  

^a Instituto Poal de Reumatologia   (Spain)

^b NONE

Author keywords

Chondroitin sulphate; Glycosaminoglycans; Osteoarthritis

Indexed keywords

CHONDROITIN SULFATE; DICLOFENAC; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN POLYSULFATE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEOGLYCAN;

ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CARCINOGENIC ACTIVITY; CARTILAGE DEGENERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GENOTOXICITY; HUMAN; KNEE OSTEOARTHRITIS; META ANALYSIS; MUTAGENIC ACTIVITY; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; REPRODUCTIVE TOXICITY; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 33749492796     PISSN: 02140659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Balint G, Szebenyi B. Diagnosis of osteoarthritis. Drugs 1996;52(Suppl 3):1-13.
2. a ed. Sociedad Española de Reumatología 2000:464.
3. Carmona L. Prevalencia e impacto de las enfermedades reumáticas en la población adulta española. Estudio EPISER: Sociedad Española de Reumatología 2001:65-71.
4. Blanco F. Óxido nítrico y cartílago articular. Condroprotección 1999;5(1):6-7.
5. Lequesne M, et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 1994;21(Suppl 41):65-71.
6. Hardingham T. Chondroitin sulfate and joint disease. Osteoarthritis and Cartilage 1998;6(Suppl A):3-5.
7. Fosang AJ, Hardingham TE. Matrix proteoglycans. En: Comper WD (ed). Extracellular Matrix. Vol 2. Netherlands: Harwood Academic Publishers 1996:200-29.
8. Hardingham TE. Articular cartilage. En: Maddison PJ, Isenberg DA, Woo P, Glass DN (eds). The Oxford Textbook of Rheumatology. Oxford: Oxford University Press 1997 (en prensa).
9. Martel-Pelletier J, et al. Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage. Arthritis Rheum 1984; 27:305-12.
10. Shinmei M, et al. The mechanism of cartilage degradation in osteoarthritic joints. Semin Arthritis Rheum 1990; 19(Suppl 1):16-20.
11. Martel-Pelletier J, et al. Neutral proteases in human osteoarthritis synovium. Arthritis Rheum 1986;29:1112-21.
12. Pelletier JP, et al. Canine osteoarthritis: effects of endogenous neutral metalloproteoglycanases on articular proteoglycans. J Orthop Rhe 1988;6:379-88.
13. Unemori EN, et al. Collagenase expression and endogenous activation in rabbit synovial fibroblasts. J Boil Chem 1988;16252-9.
14. Murphy G, et al. Stromelysin is an activator of procollagenase. Biochem J 1987;248:265-8.
15. Rath NC. Synthesis of interleukin-1-like activity by normal rat chondrocytes in culture. Clin Immunol Immunopathol 1988;47:39-46.
16. McGuire-Goldring MB, et al. In vitro activation of human chondrocytes and synoviocytes by a human interleukin-1-like factor. Arthritis Rheum 1984;27:654-62.
17. Tyler JA. Articular cartilage cultured wih catabolism synthesizes a decreased number of normal proteoglycan molecules. Biochem J 1985;227:869-78.
18. Pelletier JP, et al. Imbalance between the mechanisms of activation and inhibition of metalloproteinases in the early lesions of experimental osteoarthritis. Arthritis Rheum 33(10):1466-76.
19. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis and Cartilage 1998;6(Suppl A):14-21.
20. Blanco F. Condroitín sulfato, sulfato de glucosamina y ácido hialurónico: mecanismos de acción. Condroprotección dic. 2002.
21. Reveliere D, Mentz F, Merle-Béral H, Chevalier X. Mechanisms of cell death of articular rabbit chondrocytes induced by nitric oxide and protecting effect of chondroitine 4/6 sulfate. Artrhritis and Rheumatism 1998;41(Suppl):41.
22. Conte A, De Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneim Forsch/Drug Res 1991;41:768-72.
23. Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneim Forsch/Drug Res 1995;45:918-25.
24. Volpi N. Oral bioavailability of chondroitin sulfate and its constituents in healthy male volunteers. Osteoarthritis Cart 2002;10:768-77.
25. Gross JI, et al. Sodium chondroitin sulfate protein complexes of cartilage. II. Metabolism. J Bioi Chem 1960;235:2889-92.
26. Hutterer F, et al. Degradation of mucopolysaccarides by hepatic lysosomes. Biochim Biphys Acta 1996;115:312-9.
27. Adermann G, et al. The influence on the route of administration of the bioavailability of an endogenous macromolecule chondroitin sulfate. Eur J Drug Metabolism and Pharmacokinetics 1982;7:11-7.
28. Konador A, et al. Changes in chondroitin sulfate concentration in rabbit blood plasma depending on the method of its administration. Arch Immunol Ther Exp 1977;25:895-903.
29. Wood KM, et al. The metabolic fate of chondroitin S35-sulfate proteoglycan in the rat. Biochem Soc Trans 1975;3:500.
30. Konador A, et al. Distribution of radioactivity in the mouse organism after administration of S35-chondroitin sulfate. Folia Bioog 1976;24:177.
31. Vebruggen G. Expert report on the pharmacological and toxicological documentation, 1997.
32. Jordan KM, et al. EULAR Recommendations 2003: an evidenced based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62: 1145-55.
33. Vergés J. Condroprotección: de la utopía a la realidad. Aparato Locomotor 1998;59:13-20.
34. Vergés J. Ventajas de la utilización clínica de las moléculas denominadas SYSADOA en pacientes artrósicos. Reuma 2001;5:43-4.
35. Morreale, et al. Comparison of the antiiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. The Journal of Rheumatology 1996;23(8):1385-91.
36. max when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clinical Pharmacology and Therapeutics 2001;70(1):5-9.
37. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cart 1998;6(Suppl A):31-6.
38. Fleisch AM, Merlin C, Imhoff A, Hodelr J, Kissling R. A one-year randomized, double-blind, placebo-controlled study with oral chondroitin sulfate in patients with knee osteoarthritis. Presented in the Congress OARS 97. Singapur, 7-9 de junio 1997 (sym.9, p.70).
39. Uebelhart D, Thonar EJMA, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis and Cartilage 1998;6(Suppl A):39-46.
40. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis and Cartilage 1998;6(Suppl A):37-8.
41. Pavelka K, Bucsi L, Manopulo R. Double-blind, dose-effect study of oral CS 4&6 1200 mg, 800 mg, 200 mg against placebo in the treatment of femoro-tibial osteoarthritis. Litera Rheumatologica 1998;24:21-30.
42. Uebelhart D, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cart 2004;12:269-76.
43. Michel B, Vignon E, De Vatharie F, et al. Oral chondroitin sulfate in knee OA patients: radiographic outcomes of a 2-year prospective study. Osteoarthritis Cart 2001;9(Suppl B):LA2.
44. Verbruggen G, et al. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheum 2002;21(3): 231-41.
45. Leeb F, et al. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. The Journal of Rheumatology 2000;27(1):205-11.
46. Pelletier JP. Diagnóstico y tratamiento de la artrosis: evolución desde el tratamiento sintomático a estrategias modificadoras de la enfermedad. Condroprotección 2003;8-10.